Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 7;67(5):885–897. doi: 10.2337/db17-1150

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

PMC Copyright notice

Elevated M-acylCs impair first- and second-phase insulin release in isolated islets. M-acylC effect on GSIS was assessed in vitro by determining its dose-dependent effect on murine islets and is shown by insulin level (A) and fold response (B) to HG (n = 5/group). Insulin secretion in murine islets (n = 6/group) (C) and normal human islets (n = 4/group) (D) after a 28-h treatment with vehicle control or M-acylCs Physio and M-acylC Patho concentrations in vitro was assessed. The fold response to HG is shown as an inset. E: Insulin secretion in normal and T2D human islets (n = 5/group) was measured. Subsequently, T2D human islets were treated with M-acylCs Physio and M-acylCs Patho concentrations and insulin secretion assay was performed (n = 3/group). Fold response is shown as an inset. F: Dynamic insulin secretion was assessed in murine islets treated with M-acylCs Physio and M-acylCs Patho concentrations in vitro (n = 3/group). Area under the curve (AUC) is shown as an inset. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01; n.s, not significant.